Convergence Investment Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Convergence Investment Partners’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-20,125	Closed	-$1.2M	–	357
2018 Q2	$1.2M	Sell	20,125 -18,384	-48%	-$952K	0.17%	162
2018 Q1	$1.76M	Sell	38,509 -10,836	-22%	-$452K	0.23%	154
2017 Q4	$1.97M	Buy	49,345 +2,385	+5%	+$94.2K	0.26%	134
2017 Q3	$1.88M	Buy	46,960 +1,519	+3%	+$65.7K	0.27%	143
2017 Q2	$1.96M	Sell	45,441 -11,739	-21%	-$418K	0.29%	134
2017 Q1	$1.79M	Sell	57,180 -3,305	-5%	-$88.6K	0.25%	148
2016 Q4	$1.53M	Hold	60,485	–	–	0.21%	196
2016 Q3	$1.5M	Buy	+60,485	New	+$1.37M	0.22%	177
2015 Q4	–	Sell	-93,370	Closed	-$1.31M	–	380
2015 Q3	$1.31M	Buy	+93,370	New	+$1.74M	0.15%	220

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Convergence Investment Partners's SUPN Position: Q3 2018 in Review

Convergence Investment Partners sold out of Supernus Pharmaceuticals (SUPN) in Q3 2018, closing a stake of 20,125 shares — an estimated $1.2M sold.

Convergence Investment Partners first reported a position in SUPN in Q3 2015 and held it in 9 quarters. The position peaked at $1.97M in Q4 2017. 288 funds tracked by Wall St. Rank hold SUPN as of Q3 2018.

Convergence Investment Partners reported no remaining Supernus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Convergence Investment Partners sold 20,125 Supernus Pharmaceuticals shares in Q3 2018, an estimated $1.2M.
Convergence Investment Partners first reported a position in Supernus Pharmaceuticals in Q3 2015 and held it in 9 quarters.
Convergence Investment Partners's Supernus Pharmaceuticals position peaked at $1.97M in Q4 2017.
288 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2018.

Based on Convergence Investment Partners's 13F filing for Q3 2018, filed 13 Nov 2018.